Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

February’s top stories: GSK Phase III melanoma trial, Novavax Ebola GP vaccine

GlaxoSmithKline (GSK) reported positive overall survival (OS) results from a Phase III trial of combination melanoma drug, Novavax started enrolment in a Phase I clinical trial of its Ebola virus glycoprotein (GP) vaccine in humans and Amgen's Phase III ABP 501 trial in rheumatoid arthritis patients meets endpoints. Drugdevelopment-technology.com wraps-up key headlines from February.

Go Top